Nov,2023. Shanghai Argo Biopharmaceutical Co., LTD. (hereinafter referred to as Argo Biopharma) Completed RMB 300 million in Series A+ financing led by SDIC Investment.
Argo Biopharmal was established in April 2021 and focuses on the development of siRNA drugs. The company is headquartered in Shanghai Zhangjiang High-Tech Park and was founded by several scientists with in-depth experience in the development of RNAi drugs after returning to China. The company’s team has extensive experience in Bioinformatics and the entire process of RNAi drug development, including nucleic acid sequence design, chemical modification, GalNAc coupling technology, extrahepatic delivery technology development, and oligonucleotide CMC. Currently, four oligonucleotide projects are in the clinical stage. Some projects have shown good safety and efficacy in clinical phase 1 and are expected to enter clinical phase 2 in early 2024.
According to China CDE website recently, the siRNA drug “BW-20805 Injection” applied by Hangzhou Bolin Pharmaceutical Technology Co., Ltd.( a subsidiary of Argo Biopharma), has obtained an implicit clinical trial license (acceptance number: CXHL2300824) for the treatment of Hereditary angioedema (HAE). BW-20805 is the third siRNA drug approved for clinical trials in China by Argo Biopharma this year. The other two siRNA drugs under development that were approved for clinical trials earlier are BW-00163 and BW-00112 with indications of hypertension and dyslipidemia.
According to China CDE website previously , the Class 1 new drug BW-20507 injection submitted by Hangzhou Bolin Pharmaceutical Technology Co., Ltd has been accepted by the CDE and is planned to be developed for for the treatment of chronic hepatitis B. According to the public information, BW-20507 is a small interfering RNA (siRNA) drug independently developed by the company that targets hepatitis B virus (HBV). It is reported that the therapy has launched a Phase 1/2 clinical trial in Australia to evaluate the safety, tolerability, and pharmacokinetics in healthy subjects and patients with chronic hepatitis B virus (HBV) infection in Sep, 2023.
About Shanghai Argo Biopharmaceutical Co., LTD
Shanghai Argo Biopharmaceutical Co., LTD. (hereinafter referred to as Argo) is a newly established innovative R&D enterprise focusing on RNAi drug development. In November 2021, the company completed RMB 400 million A round of financing. Argo currently has more than ten pipelines at different stages, several of which are first-in-class and best-in-class candidates. And a newly designed modern R&D center (2900 m²)has been put into use in Sept 2022 and one GMP site (4000 m²)is under design and will start construction in 2023.[2]https://cn.linkedin.com/company/shanghai-argo-biopharmaceutical-co-ltd
References
